Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Patient Enrollment Begins in Pain Trial
RxTrials Institute Drug Pipeline Alert
March 12, 2008 | Vol. 6 No. 11
Patient Enrollment Begins in Pain Trial
Canadian drugmaker Labopharm has started its Phase III trial of its tramadol-acetaminophen product.
The multicenter, randomized, double-blind, parallel-arm study will compare the efficacy and safety of the combination product with placebo in the treatment of acute low back pain. The study will include more than 250 patients.
Many tramadol-acetaminophen combination products must be taken four to six times per day. Labopharm’s formulation has the potential to offer enhanced patient compliance through twice-daily administration, as well as an improved side effect profile, according to the company.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.